BRUCE SCHACKMAN

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi The lifetime cost of current human immunodeficiency virus care in the United States
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, New York 10021, USA
    Med Care 44:990-7. 2006
  2. ncbi Cost-effectiveness of pre-exposure prophylaxis for HIV: a review
    Bruce R Schackman
    Weill Cornell Medical College, New York, New York, USA
    Curr Opin HIV AIDS 7:587-92. 2012
  3. ncbi The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, United States Electronic address
    Drug Alcohol Depend 128:90-7. 2013
  4. ncbi Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, USA
    J Gen Intern Med 27:669-76. 2012
  5. ncbi Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti
    Bruce R Schackman
    Department of Public Health, Weill Medical College, Cornell University, New York, New York, United States of America
    PLoS Med 4:e183. 2007
  6. ncbi Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree?
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    Med Decis Making 28:233-42. 2008
  7. ncbi Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Infect Dis 43:S247-53. 2006
  8. ncbi Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095
    Bruce R Schackman
    Department of Public Health, Weill Medical College, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 46:547-54. 2007
  9. ncbi Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment
    Bruce R Schackman
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Health Care Financ Rev 26:67-80. 2005
  10. ncbi Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programs
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, 411 East 69th Street New York, NY 10021, USA
    Subst Abuse Treat Prev Policy 2:23. 2007

Research Grants

  1. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2007
  2. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
    BRUCE SCHACKMAN; Fiscal Year: 2009
  3. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
    Bruce R Schackman; Fiscal Year: 2010

Detail Information

Publications46

  1. ncbi The lifetime cost of current human immunodeficiency virus care in the United States
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, New York 10021, USA
    Med Care 44:990-7. 2006
    ..We sought to project the lifetime cost of medical care for human immunodefiency virus (HIV)-infected adults using current antiretroviral therapy (ART) standards...
  2. ncbi Cost-effectiveness of pre-exposure prophylaxis for HIV: a review
    Bruce R Schackman
    Weill Cornell Medical College, New York, New York, USA
    Curr Opin HIV AIDS 7:587-92. 2012
    ..This review examines six recent studies of the cost-effectiveness of PrEP for preventing HIV transmission in the USA and South Africa...
  3. ncbi The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, United States Electronic address
    Drug Alcohol Depend 128:90-7. 2013
    ..Fewer than half of US community-based substance abuse treatment programs make HIV testing available on-site or through referral...
  4. ncbi Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, USA
    J Gen Intern Med 27:669-76. 2012
    ..Bup/nx is off patent but not available as a generic...
  5. ncbi Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti
    Bruce R Schackman
    Department of Public Health, Weill Medical College, Cornell University, New York, New York, United States of America
    PLoS Med 4:e183. 2007
    ..We compared the cost-effectiveness, projected health outcomes, and annual cost of screening pregnant women using a rapid syphilis test as part of scaled-up prenatal testing to prevent mother-to-child HIV transmission in Haiti...
  6. ncbi Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree?
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    Med Decis Making 28:233-42. 2008
    ..Subjects completed rating scale and standard gamble evaluations of current health and hypothetical descriptions of HCV symptoms and treatment side effects on a scale from 0 (death or worse than death) to 1 (best possible health)...
  7. ncbi Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Infect Dis 43:S247-53. 2006
    ....
  8. ncbi Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095
    Bruce R Schackman
    Department of Public Health, Weill Medical College, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 46:547-54. 2007
    ..We rigorously examined associations over time among race, virologic failure, 4 self-reported adherence metrics, and quality of life (QOL)...
  9. ncbi Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment
    Bruce R Schackman
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Health Care Financ Rev 26:67-80. 2005
    ....
  10. ncbi Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programs
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, 411 East 69th Street New York, NY 10021, USA
    Subst Abuse Treat Prev Policy 2:23. 2007
    ....
  11. ncbi Offers of hepatitis C care do not lead to treatment
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, 411 East 69th Street, New York, NY 10021, USA
    J Urban Health 84:455-8. 2007
    ..Whereas offers of HCV treatment may be increasing, there is a need to improve continuity of care, patient-provider communication, and patient education regarding HCV treatment options for treatment rates to improve...
  12. ncbi Sexually active HIV-positive patients frequently report never using condoms in audio computer-assisted self-interviews conducted at routine clinical visits
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, New York 10021, USA
    AIDS Patient Care STDS 22:123-9. 2008
    ..ACASI interviews may be an effective way of identifying patients in clinical settings who require prevention counseling as well as other psychosocial services...
  13. ncbi Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS
    Bruce R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Med Decis Making 22:27-38. 2002
    ....
  14. ncbi The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, New York 10021, USA
    AIDS 22:2025-33. 2008
    ..To evaluate the clinical impact and cost-effectiveness of HLA-B*5701 testing to guide selection of first-line HIV regimens in the United States...
  15. ncbi Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10021, USA
    Clin Infect Dis 45:1062-70. 2007
    ..We projected the long-term outcomes of this treatment simplification strategy to inform the design of a proposed multicenter, randomized clinical trial...
  16. ncbi Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults
    Bruce R Schackman
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Arch Intern Med 162:2478-86. 2002
    ....
  17. ncbi How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?
    Bruce R Schackman
    Division of Outcomes and Effectiveness Research, Department of Public Health, Weill Medical College of Cornell University, New York 10021, USA
    Pharmacoeconomics 22:293-300. 2004
    ..Sensitivity analyses for health-related QOL (HR-QOL), cost and discount rate economic parameters are of particular interest because they measure the effects of methodological and estimation uncertainties...
  18. ncbi The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women
    Bruce R Schackman
    Divisions of Outcomes and Effectiveness, Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    AIDS 18:1827-34. 2004
    ....
  19. ncbi The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 56:S76-82. 2011
    ..Implementing integrated HIV and buprenorphine/naloxone treatment requires cost estimates to plan and obtain funding...
  20. ncbi Implementation science for the prevention and treatment of HIV/AIDS
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 55:S27-31. 2010
    ....
  21. ncbi The cost of HIV medication adherence support interventions: results of a cross-site evaluation
    B R Schackman
    Weill Medical College of Cornell University, New York, USA
    AIDS Care 17:927-37. 2005
    ..Payers should consider enhanced reimbursement for adherence support services...
  22. ncbi Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY, USA
    AIDS Care 21:992-9. 2009
    ..ACASI screening should be considered in HIV clinical care settings to assist providers in identifying patients with the greatest need for targeted psychosocial services including adherence support and depression care...
  23. ncbi Design issues in initial HIV-treatment trials: focus on ACTG A5095
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, USA
    Antivir Ther 11:751-60. 2006
    ..We also hope to inform the field regarding issues in choosing composite versus virological endpoints as well as other key considerations in trial design and monitoring...
  24. ncbi Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
    ..There were no significant differences among subgroups with respect to treatment responses. These results demonstrate the potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 counts...
  25. ncbi Can urban methadone patients complete health utility assessments?
    Paul A Teixeira
    Division of Health Policy, Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    Patient Educ Couns 71:302-7. 2008
    ..An estimated 65-90% of MMT patients are chronically infected with HCV...
  26. ncbi Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting
    Serena P Koenig
    Division of Global Health Equity, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Infect Dis 51:600-8. 2010
    ..Laboratory monitoring for toxicity among patients receiving antiretroviral therapy (ART) in less-developed settings is technically challenging and consumes significant resources...
  27. ncbi Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India
    Melissa A Bender
    Divisions of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 50:416-25. 2010
    ..We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine...
  28. ncbi Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Diseases and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 43:S113-8. 2006
    ..Adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds...
  29. ncbi Achieving effective antidepressant pharmacotherapy in primary care: the role of depression care management in treating late-life depression
    Yuhua Bao
    Division of Health Policy, Department of Public Health, Weill Cornell Medical College, New York, NewYork, USA
    J Am Geriatr Soc 57:895-900. 2009
    ..To estimate the effect of an evidence-based depression care management (DCM) intervention on the initiation and appropriate use of antidepressant in primary care patients with late-life depression...
  30. ncbi Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    N Engl J Med 350:1850-61. 2004
    ....
  31. ncbi A cost-benefit analysis of external hip protectors in the nursing home setting
    Lisa A Honkanen
    Division of Geriatrics and Gerontology, Joan and Sanford Weill Medical College, Cornell University, New York, New York 10021, USA
    J Am Geriatr Soc 53:190-7. 2005
    ..To estimate potential cost savings generated by a program of hip protectors in the nursing home from a Medicare perspective...
  32. ncbi Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 51:392-400. 2010
    ..We forecast outcomes of this approach if implemented in Washington DC...
  33. ncbi Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
    Heather Taffet Gold
    Department of Public Health, Weill Cornell Medical College, New York, NY, USA
    Cancer 115:3858-67. 2009
    ....
  34. ncbi Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial
    Roy M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
    JAMA 296:769-81. 2006
    ..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen...
  35. ncbi Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression
    Roy M Gulick
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    AIDS 21:813-23. 2007
    ..To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection...
  36. ncbi Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
    Lisa A Honkanen
    Division of Geriatrics and Gerontology, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Am Geriatr Soc 54:1658-65. 2006
    ..To estimate the cost-effectiveness from a societal perspective of a hip protector (HP) program over the remaining lifetime of individuals initially living at home...
  37. ncbi Variation in orthopaedic surgeons' perceptions about the indications for rotator cuff surgery
    Warren R Dunn
    The Hospital for Special Surgery, 525 East 70th Street, New York, NY 10021, USA
    J Bone Joint Surg Am 87:1978-84. 2005
    ..The purpose of the current study was to characterize orthopaedic surgeons' attitudes concerning medical decision-making about rotator cuff surgery and to investigate the associations between these beliefs and reported surgical volumes...
  38. ncbi A synthesis of cost-utility analysis literature in infectious disease
    Patricia W Stone
    Columbia University School of Nursing, New York, NY 10032, USA
    Lancet Infect Dis 5:383-91. 2005
    ..The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed...
  39. ncbi Response to commentary by Dr. Oliver and colleagues on hip protectors
    Lisa A Honkanen
    J Am Geriatr Soc 54:1159-60. 2006
  40. ncbi Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
    Daniel R Kuritzkes
    Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
    J Infect Dis 197:867-70. 2008
    ..27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy...
  41. ncbi The quality of highly regarded adolescent substance abuse treatment programs: results of an in-depth national survey
    Rosalind Brannigan
    Drug Strategies, 1755 Massachusetts Avenue NW, Washington, DC 20036 2103, USA
    Arch Pediatr Adolesc Med 158:904-9. 2004
    ..Drug and alcohol abuse and dependence are the most prevalent causes of adolescent morbidity and mortality in the United States. Effective, accessible treatment for adolescents with substance abuse problems is urgently needed...
  42. ncbi Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs
    A David Paltiel
    Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut 06520 8034, USA
    Ann Intern Med 145:797-806. 2006
    ..An extensive literature supports expanded HIV screening in the United States. However, the question of whom to test and how frequently remains controversial...
  43. ncbi Variations in self-rated health among patients with HIV infection
    Joseph M Mrus
    Health Services Research and Development, Cincinnati VA Medical Center, Cincinnati, OH, USA
    Qual Life Res 15:503-14. 2006
    ....
  44. ncbi The survival benefits of AIDS treatment in the United States
    Rochelle P Walensky
    Division of Infectious Disease and General Medicine, Massachusetts General Hospital, Boston 02114, USA
    J Infect Dis 194:11-9. 2006
    ..As widespread adoption of potent combination antiretroviral therapy (ART) reaches its tenth year, our objective was to quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United States...
  45. ncbi The use of an educational video during informed consent in an HIV clinical trial in Haiti
    Patrice Joseph
    Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, GHESKIO, Port au Prince, Haiti
    J Acquir Immune Defic Syndr 42:588-91. 2006
    ..CONCLUSIONS: Informed consent using an educational video ensured good comprehension in most of the volunteers. Additional educational sessions may be necessary for some participants with lower educational level...
  46. ncbi Preventing vertical hepatitis C virus transmission
    Bruce R Schackman
    Clin Infect Dis 45:802. 2007

Research Grants4

  1. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2007
    ..This work will provide insight into important policy questions identified by the NIH Consensus Development Conference on the Management of Hepatitis C in June 2002 and will inform development of treatment and reimbursement guidelines. ..
  2. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
    BRUCE SCHACKMAN; Fiscal Year: 2009
    ....
  3. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
    Bruce R Schackman; Fiscal Year: 2010
    ....